Cargando…

248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity

BACKGROUND: Despite years of published data describing the increased risk of nephrotoxicity with use of vancomycin and piperacillin/tazobactam (VPT), this combination remains one of the most utilized antibiotic combinations at our institution. There is limited data describing the appropriateness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Son, Andrea, Murphy, Nina Naeger, Wadsworth, Christina, Bogorodskaya, Milana, Hecker, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777050/
http://dx.doi.org/10.1093/ofid/ofaa439.292
_version_ 1783630815725355008
author Son, Andrea
Murphy, Nina Naeger
Wadsworth, Christina
Bogorodskaya, Milana
Hecker, Michelle
author_facet Son, Andrea
Murphy, Nina Naeger
Wadsworth, Christina
Bogorodskaya, Milana
Hecker, Michelle
author_sort Son, Andrea
collection PubMed
description BACKGROUND: Despite years of published data describing the increased risk of nephrotoxicity with use of vancomycin and piperacillin/tazobactam (VPT), this combination remains one of the most utilized antibiotic combinations at our institution. There is limited data describing the appropriateness of empiric use of this broad-spectrum regimen. Our primary objective was to evaluate the appropriateness of the anti-methicillin resistant Staphylococcus aureus (MRSA), anti-pseudomonal, and anti-anaerobic spectrum of activity for patients empirically treated with this combination. Our secondary objective was to evaluate the appropriateness of diagnostic evaluation in patients started on this combination. METHODS: A retrospective cohort study was performed on a random sample of unique patients prescribed the combination of VPT from October 2019 through March 2020. Demographic and clinical data were abstracted from the electronic medical record. Based on predetermined criteria, we evaluated the appropriateness of the spectrum of activity of empiric therapy and the diagnostic evaluation. RESULTS: Of 100 patients evaluated, 96 patients (96%) received VPT as empiric treatment. The indications for use are shown in Table 1. Pneumonia and soft tissue/bone/joint infections were the most common indications. The appropriateness of anti-MRSA, anti-pseudomonal, and anti-anaerobic therapy is shown in Table 2. In only 35% of patients was the full spectrum of activity appropriate. Of 47 patients treated empirically for pneumonia, 35 (74%) had an order for a respiratory culture and 7 (15%) for a nasal MRSA surveillance culture. Of 30 patients treated empirically for soft tissue//joint infections, wound cultures were obtained in 22 (73%). Nineteen patients underwent surgical intervention, of whom 17 (89%) had cultures obtained. Table 1. Indications for Empiric Vancomycin and Piperacillin/tazobactam Combination Therapy [Image: see text] Table 2: Appropriateness of Spectrum of Activity for Empiric Vancomycin and Piperacillin/tazobactam Combination Therapy [Image: see text] CONCLUSION: At our institution VPT use was usually empiric and unnecessarily broad for the syndrome being treated. Microbiologic testing was suboptimal and may have resulted in prolonged therapy. Although interventions aimed at de-escalating VPT are useful, interventions aimed at ensuring appropriate empiric use of this combination and ensuring appropriate diagnostic testing may be just as important. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7777050
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77770502021-01-07 248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity Son, Andrea Murphy, Nina Naeger Wadsworth, Christina Bogorodskaya, Milana Hecker, Michelle Open Forum Infect Dis Poster Abstracts BACKGROUND: Despite years of published data describing the increased risk of nephrotoxicity with use of vancomycin and piperacillin/tazobactam (VPT), this combination remains one of the most utilized antibiotic combinations at our institution. There is limited data describing the appropriateness of empiric use of this broad-spectrum regimen. Our primary objective was to evaluate the appropriateness of the anti-methicillin resistant Staphylococcus aureus (MRSA), anti-pseudomonal, and anti-anaerobic spectrum of activity for patients empirically treated with this combination. Our secondary objective was to evaluate the appropriateness of diagnostic evaluation in patients started on this combination. METHODS: A retrospective cohort study was performed on a random sample of unique patients prescribed the combination of VPT from October 2019 through March 2020. Demographic and clinical data were abstracted from the electronic medical record. Based on predetermined criteria, we evaluated the appropriateness of the spectrum of activity of empiric therapy and the diagnostic evaluation. RESULTS: Of 100 patients evaluated, 96 patients (96%) received VPT as empiric treatment. The indications for use are shown in Table 1. Pneumonia and soft tissue/bone/joint infections were the most common indications. The appropriateness of anti-MRSA, anti-pseudomonal, and anti-anaerobic therapy is shown in Table 2. In only 35% of patients was the full spectrum of activity appropriate. Of 47 patients treated empirically for pneumonia, 35 (74%) had an order for a respiratory culture and 7 (15%) for a nasal MRSA surveillance culture. Of 30 patients treated empirically for soft tissue//joint infections, wound cultures were obtained in 22 (73%). Nineteen patients underwent surgical intervention, of whom 17 (89%) had cultures obtained. Table 1. Indications for Empiric Vancomycin and Piperacillin/tazobactam Combination Therapy [Image: see text] Table 2: Appropriateness of Spectrum of Activity for Empiric Vancomycin and Piperacillin/tazobactam Combination Therapy [Image: see text] CONCLUSION: At our institution VPT use was usually empiric and unnecessarily broad for the syndrome being treated. Microbiologic testing was suboptimal and may have resulted in prolonged therapy. Although interventions aimed at de-escalating VPT are useful, interventions aimed at ensuring appropriate empiric use of this combination and ensuring appropriate diagnostic testing may be just as important. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7777050/ http://dx.doi.org/10.1093/ofid/ofaa439.292 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Son, Andrea
Murphy, Nina Naeger
Wadsworth, Christina
Bogorodskaya, Milana
Hecker, Michelle
248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity
title 248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity
title_full 248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity
title_fullStr 248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity
title_full_unstemmed 248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity
title_short 248. Why so Much Vancomycin and Piperacillin/Tazobactam Usage Given Known Risks of Nephrotoxicity
title_sort 248. why so much vancomycin and piperacillin/tazobactam usage given known risks of nephrotoxicity
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777050/
http://dx.doi.org/10.1093/ofid/ofaa439.292
work_keys_str_mv AT sonandrea 248whysomuchvancomycinandpiperacillintazobactamusagegivenknownrisksofnephrotoxicity
AT murphyninanaeger 248whysomuchvancomycinandpiperacillintazobactamusagegivenknownrisksofnephrotoxicity
AT wadsworthchristina 248whysomuchvancomycinandpiperacillintazobactamusagegivenknownrisksofnephrotoxicity
AT bogorodskayamilana 248whysomuchvancomycinandpiperacillintazobactamusagegivenknownrisksofnephrotoxicity
AT heckermichelle 248whysomuchvancomycinandpiperacillintazobactamusagegivenknownrisksofnephrotoxicity